At the IGTP TODAY

News

Artificial intelligence and advanced therapies are the focus of the ICS Conference, hosted by IGTP

The 14th Research Conference of the ICS focused on the transformative potential of research in the health system and awarded prizes to eight researchers. Antoni Bayés and Alejandro Bustamante, who work at the Hospital and researchers at IGTP, were awarded a prize for the best hospital scientific career and ICS young researcher, respectively.

IGTP researchers engage in World Cancer Research Day with talks and workshops

  • In collaboration with the Badalona City Council, a series of events and talks organised to mark the 40th anniversary of the Germans Trias Hospital will deal with topics related to science and health.
  • The event on Sunday at the Badalona Museum is organised by Amics de Can Ruti and will feature researchers from the Germans Trias i Pujol Research Institute (IGTP) and the Catalan Institute of Oncology (ICO).

Latest episode of IGTP’s 'Un Bri de Ciència' takes on viral hepatitis

To mark World Hepatitis Day, the podcast 'Un Bri de Ciència' dedicates an episode to viral hepatitis, specifically focusing on Hepatitis B and C, which are considered to be the most severe types. Researcher Elisa Martró unravels what we know about these diseases and discusses her projects, both in the hospital setting and in communities, working with vulnerable populations. The podcast enhances the mission of awareness and dissemination of IGTP.

IGTP's latest platform: the Biostatistics Unit

The Biostatistics Unit is made up by a team of statisticians and mathematicians who conduct and support biomedical research primarily at the Can Ruti Campus, and also in collaboration with other public or private organizations. The Unit has recently been introduced to the technologies and services provided by the Germans Trias i Pujol Research Institute (IGTP).

- Campus Can Ruti, Research

New lung cancer treatment boosts survival and could benefit more than 6,000 patients a year

A new lung cancer treatment has allowed 36.8% of patients to achieve complete tumour disappearance, compared to the 6.9% rate of the standard post-surgery treatment. In addition, 85% of patients survive two years after receiving chemo-immunotherapy before surgery compared to 63% who receive chemotherapy alone before surgery. The study involved oncologist from ICO Badalona and IGTP researcher, Teresa Morán.